InvestSMART

Imricor Medical Systems Inc (ASX: IMR) - Announcements

Current share price for IMR : $1.893 0.058 (3.13%)+

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$679 Annual Report to shareholders 9 Apr 2024 8:54AM $0.550 $1.893 risen by 244.09%
$679 Cleansing Notice 8 Apr 2024 1:03PM $0.555 $1.893 risen by 240.99%
$679 Application for quotation of securities - IMR 8 Apr 2024 12:22PM $0.555 $1.893 risen by 240.99%
$679 Amsterdam UMC Restarts MRI Guided Procedures with NorthStar 5 Apr 2024 9:44AM $0.590 $1.893 risen by 220.76%
$679 Completion of Placement of Entitlement Issue Shortfall 2 Apr 2024 12:51PM $0.545 $1.893 risen by 247.25%
$679 IDE Approval of NorthStar 3D from FDA in VISABL-AFL Trial 26 Mar 2024 9:35AM $0.565 $1.893 risen by 234.96%
$679 Ceasing to be a substantial holder 19 Mar 2024 10:50AM $0.495 $1.893 risen by 282.32%
$679 Results of Meeting 19 Mar 2024 10:47AM $0.495 $1.893 risen by 282.32%
$679 Imricor to Present at NWR Virtual Healthcare Conference 19 Mar 2024 9:23AM $0.495 $1.893 risen by 282.32%
$679 Ethics Committee Approval by ICPS for VISABL-AFL Trial 11 Mar 2024 9:46AM $0.470 $1.893 risen by 302.66%
$679 Ethics Committee Approval at CHUV for VISABL-AFL Trial 8 Mar 2024 8:27AM $0.460 $1.893 risen by 311.41%
$679 CE Mark Approval in EU for Vision-MR Diagnostic Catheter 6 Mar 2024 9:23AM $0.465 $1.893 risen by 306.99%
$679 FY23 Results Investor Presentation 5 Mar 2024 8:18AM $0.480 $1.893 risen by 294.27%
$679 Appendix 3Y - PM 1 Mar 2024 6:31PM $0.470 $1.893 risen by 302.66%
$679 Imricor Releases FY23 Results 29 Feb 2024 8:37AM $0.500 $1.893 risen by 278.50%
$679 Appendix 4E and FY23 Financial Accounts 29 Feb 2024 8:37AM $0.500 $1.893 risen by 278.50%
$679 Application for quotation of securities - IMR 28 Feb 2024 9:17AM $0.470 $1.893 risen by 302.66%
$679 Notice of Extraordinary General Meeting/Proxy Form 27 Feb 2024 4:33PM $0.470 $1.893 risen by 302.66%
$679 FY23 Results Webinar 27 Feb 2024 9:32AM $0.500 $1.893 risen by 278.50%
$679 Completion of Retail Entitlement Offer 27 Feb 2024 9:16AM $0.500 $1.893 risen by 278.50%
$679 Reminder of Retail Entitlement Offer Closing Date 21 Feb 2024 8:20AM $0.450 $1.893 risen by 320.56%
$679 Cleansing Notice 13 Feb 2024 5:13PM $0.450 $1.893 risen by 320.56%
$679 Application for quotation of securities - IMR 9 Feb 2024 11:37AM $0.430 $1.893 risen by 340.12%
$679 Ineligible Securityholder Letter 8 Feb 2024 9:48AM $0.545 $1.893 risen by 247.25%
$679 Eligible Securityholder Letter 8 Feb 2024 9:46AM $0.545 $1.893 risen by 247.25%

201 - 225 of 599 results

Page 9 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.